## 2.0 Synopsis

<table>
<thead>
<tr>
<th>AbbVie Inc.</th>
<th>Individual Study Table Referring to Part of Dossier:</th>
<th>(For National Authority Use Only)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name of Study Drug:</strong></td>
<td><strong>Volume:</strong></td>
<td><strong>Page:</strong></td>
</tr>
<tr>
<td>Risankizumab (BI 655066, ABBV-066)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Name of Active Ingredient:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risankizumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Title of Study:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BI 655066/ABBV-066 (Risankizumab) versus Ustekinumab and Placebo Comparators in a Randomized Double Blind Trial for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Coordinating Investigator:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univ. Prof. Dr. Hervé Bachelez</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study Sites:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>64 sites across 10 countries: Austria, Belgium, Canada, France, Germany, Mexico, Poland, Portugal, Spain, and US</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Publications:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Studied Period (Years):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First Subject First Visit: 01 March 2016</td>
<td>Phase of Development: 3</td>
<td></td>
</tr>
<tr>
<td>Last Subject Last Visit: 04 September 2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The main objectives of this study were to assess the efficacy and safety of risankizumab, compared to ustekinumab and placebo, in subjects with moderate to severe chronic plaque psoriasis. In addition, this study was to assess pharmacokinetics (PK) and the emergence of anti-drug antibodies and their effect on efficacy and safety.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methodology:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>This Phase 3, multi-center, multi-national, randomized, double-blind, double dummy, placebo- and active-comparator-controlled, parallel design study compared risankizumab to ustekinumab and placebo in subjects with moderate to severe chronic plaque psoriasis. In Part A, the co-primary efficacy endpoints were evaluated at Week 16. In addition, at Week 16, all subjects initially randomized to placebo began receiving 150 mg risankizumab. Subjects were to continue to receive treatment through Week 40 and were to be followed through at least Week 52 when additional endpoints were evaluated. Safety was evaluated throughout the study period. Subjects who completed the study could enter the open-label extension study (Study M15-997) provided they met eligibility criteria and desired to continue treatment. Subjects who entered the open-label extension did not have a follow-up visit for this study. Subjects who discontinued prematurely or did not continue in the open-label study were to have a final visit after their last dose of study drug.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Number of Subjects (Planned and Analyzed):
Approximately 500 subjects planned; 491 analyzed

### Diagnosis and Main Criteria for Inclusion:
Subjects enrolled in this study were to be adults ≥ 18 years of age with stable moderate to severe chronic plaque psoriasis of ≥ 6 months duration; with or without psoriatic arthritis; body surface area involvement ≥ 10%; psoriasis activity and severity index (PASI) ≥ 12; Static Physician Global Assessment (sPGA) ≥ 3; and candidates for systemic therapy or phototherapy. Subjects who had non-plaque forms of psoriasis, current drug-induced psoriasis, active ongoing inflammatory diseases other than psoriasis, were taking restricted medications, had chronic or relevant acute infections, such as human immunodeficiency virus, viral hepatitis, or active tuberculosis, who had previously received risankizumab, or were pregnant, nursing, or planned to become pregnant were to be excluded.

### Test Product, Dose/Strength/Concentration, Mode of Administration and Lot Number:

<table>
<thead>
<tr>
<th>Study Drug</th>
<th>Dosage Form</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Bulk Lot Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risankizumab</td>
<td>Injection solution for subcutaneous (SC) use</td>
<td>Injection solution of risankizumab in 4.4 mM succinate buffer, pH 6.2, 225 mM sorbitol and 0.02% polysorbate 20, presented in a 1-mL prefilled syringe (PFS) with 0.87 mL (total dispensed volume was 0.83 mL).</td>
<td>Boehringer Ingelheim Pharma GmbH &amp; Co. KG</td>
<td>B151002457/505410, B151002455/505411, B151002941/505413</td>
</tr>
<tr>
<td>Risankizumab placebo</td>
<td>Injection solution for SC use</td>
<td>0.9% sodium chloride solution presented in a 1-mL PFS with 0.87 mL (total dispensed volume was 0.83 mL).</td>
<td>Boehringer Ingelheim Pharma GmbH &amp; Co. KG</td>
<td>B151001739, B151002749</td>
</tr>
</tbody>
</table>

### Duration of Treatment:
Up to 40 weeks
Reference Therapy, Dose/Strength/Concentration and Mode of Administration and Lot Number:

<table>
<thead>
<tr>
<th>Study Drug</th>
<th>Dosage Form</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Bulk Lot Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ustekinumab</td>
<td>Injection solution for SC use</td>
<td>Water for injection, sucrose, L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, presented in a 0.5-mL or 1-mL PFS (total dispensed volume was 0.5 mL or 1 mL).</td>
<td>Janssen-Cilag</td>
<td>B151002715/FDS0VME B151002717/FCS4SMG B161001665/FHS3YMF B161001666/FSK06NB B161003339/GCS2YMW</td>
</tr>
<tr>
<td>Placebo</td>
<td>Injection solution for SC use</td>
<td>0.9% sodium chloride solution presented in a 0.5-mL or 1-mL PFS. Dispensed volume was 0.5 mL or 1 mL.</td>
<td>Boehringer</td>
<td>B151001616 B151002085 B161000967 B161000967 B161001068</td>
</tr>
</tbody>
</table>

Criteria for Evaluation

Efficacy:
The co-primary endpoints in Part A were the proportion of subjects achieving ≥ 90% reduction from baseline PASI score (PASI 90) and an sPGA score of clear or almost clear at Week 16 between risankizumab and placebo.

Ranked secondary endpoints included the following:
1. Risankizumab is not different from placebo with respect to achieving sPGA of clear at Week 16
2. Risankizumab is not different from placebo with respect to PASI 100 response at Week 16
3. Risankizumab is not different from placebo with respect to achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 at Week 16
4. Risankizumab is not different from placebo with respect to achieving a Psoriasis Symptoms Scale (PSS) score of 0 at Week 16
5. Risankizumab is not different from ustekinumab with respect to PASI 90 response at Week 16
6. Risankizumab is not different from ustekinumab with respect to achieving an sPGA of clear or almost clear at Week 16
7. Risankizumab is not different from ustekinumab with respect to PASI 100 response at Week 16
8. Risankizumab is not different from ustekinumab with respect to achieving an sPGA of clear at Week 16
9. Risankizumab is not different from ustekinumab with respect to PASI 90 response at Week 52
10. Risankizumab is not different from ustekinumab with respect to PASI 100 response at Week 52
11. Risankizumab is not different from ustekinumab with respect to achieving an sPGA of clear at Week 52
Criteria for Evaluation (Continued)

Efficacy (Continued):
12. Risankizumab is not different from ustekinumab with respect to PASI 75 response at Week 12
13. Risankizumab is not different from ustekinumab with respect to achieving an sPGA of clear or
    almost clear at Week 12
14. Risankizumab is not different from ustekinumab with respect to achieving a DLQI score of 0 or 1 at
    Week 16
15. Risankizumab is not different from placebo with respect to mean change from baseline in PSS total
    score at Week 16

Other secondary endpoints included the following:
- Achievement of PASI 75 at Week 16
- Achievement of an sPGA score of clear or almost clear at Week 52
- Achievement of PASI 75 at Week 52

Pharmacokinetic:
Risankizumab plasma concentrations were determined. For immunogenicity assessment, anti-drug-
antibodies (ADAs) and neutralizing antibodies (NAb) against risankizumab were determined.

Safety:
Safety evaluations included collection of adverse events (AEs), clinical laboratory values, physical
examinations, and local tolerability.

Statistical Methods

Efficacy:
Efficacy analyses were based on the intent-to-treat principle, comprising all subjects who were
randomized. Treatment effect was evaluated based on a two-sided significance level of 0.05.

Pharmacokinetic:
Descriptive statistics for risankizumab plasma concentrations for each sampling time (study visit) were
calculated. Immunogenicity (ADA and NAb) data were summarized across specific time periods
(Weeks 0 to 16 and Weeks 0 to 52) as well as by visit. Risankizumab plasma concentrations were
compared by ADA and NAb status (positive or negative) by visit.

Safety:
Safety analyses included reporting of AEs, laboratory, physical examination (including vital signs and
12-lead electrocardiogram), and local tolerability. Safety summaries are provided using the Safety
Analysis Set, which consists of all subjects who received at least 1 dose of study medication. For safety
parameters, the treatment that was actually used by the subject was applied in the analysis (an as-treated
analysis). All AEs described in this report were considered treatment-emergent, defined as any event
with an onset after the first dose of study drug and with an onset date within 105 days after the last dose
of study drug in the analysis period, or prior to the first dose in the subsequent period for subjects who
entered into the subsequent period.
**Summary/Conclusions**

**Efficacy Results:**

The co-primary endpoints were proportions of subjects who achieved PASI 90 and who achieved sPGA clear or almost clear at Week 16, and both endpoints were achieved with statistically significant differences in favor of risankizumab. In addition, statistically significant differences were observed in all ranked secondary endpoints in Part A. These findings were supported by results at other response levels that were not specified as ranked endpoints (e.g., PASI 75 at Week 16), where risankizumab was also superior to placebo and ustekinumab.

In Part B, subjects originally randomized to risankizumab or ustekinumab continued to receive their assigned study drug every 12 weeks (q12w). Those originally randomized to placebo began receiving risankizumab at Week 16 and continued to do so q12w. All ranked secondary endpoints in Part B were met as well, with risankizumab consistently demonstrating superiority to ustekinumab at all PASI and sPGA response levels.

Overall, risankizumab was superior to ustekinumab in producing clear or almost clear skin over 52 weeks, as demonstrated by statistically significant differences between risankizumab and ustekinumab groups in proportions of subjects who achieved PASI 90, PASI 100, and sPGA clear or almost clear at Weeks 12, 16, and 52. Subjects who received continuous risankizumab generally saw persistent levels of PASI 90 and sPGA clear or almost clear responses that were achieved at Week 16, while PASI 100 and sPGA of clear responses continued to improve after Week 16, with approximately 60% of subjects achieving complete clearance at Week 52. Those subjects who initially received placebo and switched to risankizumab also experienced substantial improvements in disease severity.

In addition, statistically significant differences in favor of risankizumab treatment were observed between the risankizumab and placebo groups on measures of improvement of nail psoriasis, palmoplantar psoriasis, and scalp psoriasis at Week 16. These improvements generally persisted with continued risankizumab treatment.

**Pharmacokinetic Results:**

Following administration of risankizumab 150 mg subcutaneous (SC) dose at Weeks 0 and 4 and then q12w in subjects with moderate to severe plaque psoriasis, geometric mean trough plasma concentrations at Weeks 4 and 16 were 5.57 µg/mL and 1.72 µg/mL, respectively, and from Weeks 28 through 52, the geometric mean trough plasma concentrations ranged from 1.48 µg/mL to 1.54 µg/mL. In subjects who received at least 1 dose of risankizumab, pre-existing ADAs were detected in 4% (17/386) of subjects, and the incidence of ADAs (treatment emergent) following treatment with risankizumab was approximately 19% (75/395), with approximately half of these subjects positive for NAbs. Most subjects who were ADA positive had relatively low titers, with 7 subjects having titers over 100. Risankizumab steady-state trough geometric mean plasma concentrations ranged from approximately 0.9 to 1.3 µg/mL in subjects who were ADA positive compared to approximately 1.6 to 1.8 µg/mL for subjects who were ADA negative. Further assessment of the potential impact of ADAs on risankizumab plasma exposures was conducted as part of the population PK analyses using pooled data from all Phase 3 trials.
Summary/Conclusions (Continued)

Safety Results:
Adverse event profiles were generally comparable between the risankizumab, placebo, and ustekinumab treatment groups through Week 16 of the study with no clinically meaningful differences observed. In addition, the AE rates were similar in the ustekinumab group compared to the continuous risankizumab group through Week 52. The rates of serious AEs, AEs leading to discontinuation of study drug, severe AEs, and AEs of safety interest were generally low. The event/100 patient-year rate in the all risankizumab-treated group across the entire study was comparable to the rates observed through Week 16. There were 2 deaths in the study, including 1 subject who died outside of the treatment-emergent window from an unknown cause and 1 subject who died due to an adjudicated cardiovascular (CV) death. Two cases of major adverse CV events and an additional report of unstable angina requiring hospitalization were reported by subjects in the risankizumab group. While there were some numerically lower AE rates in the risankizumab groups compared to the ustekinumab groups in both parts of the study, the randomization ratio was skewed in favor of the risankizumab and the event numbers were too low to make any conclusions. There were no notable changes in laboratory values in the study, and no indications of liver injury. Overall, risankizumab was well tolerated and offered a favorable benefit-risk profile.

Conclusions:
The superior benefits of risankizumab compared with placebo and ustekinumab were consistently demonstrated by the primary and secondary endpoints in this Phase 3 study in subjects with moderate to severe plaque psoriasis. This treatment was shown to be well-tolerated with no meaningful differences from placebo and a comparable safety profile to that of ustekinumab. Overall, the benefit-risk profile for risankizumab was favorable. Therefore, this study supports risankizumab as an effective and well-tolerated treatment option for patients with moderate to severe plaque psoriasis.

Date of Report: 27Dec2017